Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
- Registration Number
- NCT06363123
- Lead Sponsor
- Beijing Friendship Hospital
- Brief Summary
The aim of this observational study is to comprehensively analyze the metabolites in plasma samples from multi-cancer patients using advanced mass spectrometry detection technology, in conjunction with metabolomics approaches. The goal is to construct a plasma metabolite database for multi-cancer patients. Simultaneously, we will delve into the exploration a...
- Detailed Description
Firstly, a wide-targeted metabolomic measurement will be conducted on all samples to identify potential metabolite candidate markers and analyze differences in the metabolic profiles of patients with different types of cancer. Additionally, a comprehensive metabolite database specific to cancer patients will be constructed.
...
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 2700
-
Multi-Cancer Group:
- Patients with a confirmed diagnosis based on the clinical "gold standard".
- Collection of plasma samples prior to treatment.
- Availability of complete clinical data.
-
Control Group:
- Individuals with no abnormalities in routine physical examinations and relevant clinical tests.
- Age ≥ 45 years.
- Availability of complete clinical data.
- Previous reception of anti-tumor treatments (including radiotherapy, chemotherapy, etc.) before blood collection.
- Coexistence of other systemic tumors.
- Absence of plasma sample collection before treatment.
- Pregnancy status.
- No clear evidence of histopathological diagnosis (not applicable to the control group based on this criterion).
- Patients with severe acute infections.
- Patients with severe anemia.
- Patients with severe liver or kidney dysfunction.
- Patients with autoimmune deficiency diseases.
- Patients with Hyperlipidemia.
- Patients received contrast agent injection before blood draw.
- Patients with psychiatric disorders.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma metabolite content Before receiving treatment for cancer The outcome will be tested by metabolomics detection technology based on mass spectrometry
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (4)
Beijing Friendship Hospital, Capital Medical University
🇨🇳Beijing, Beijing, China
Hebei Tumor Hospital
🇨🇳Shijiazhuang, Hebei, China
Cancer Hospital Chinese Academy of Medical Sciences
🇨🇳Beijing, Beijing, China
Zhejiang Cancer Hospital
🇨🇳Hangzhou, Zhejiang, China